First Wave BioPharma, Inc.

Symbol: FWBI

NASDAQ

3.4199

USD

Market price today

  • -0.3376

    P/E Ratio

  • 0.0013

    PEG Ratio

  • 6.93M

    MRK Cap

  • 0.00%

    DIV Yield

First Wave BioPharma, Inc. (FWBI) Stock Price & Analysis

Shares Outstanding

2.03M

Gross Profit Margin

0.00%

Operating Profit Margin

0.00%

Net Profit Margin

0.00%

Return on Assets

-2.30%

Return on Equity

-6.04%

Return on Capital Employed

-4.21%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Mr. James R. Sapirstein M.B.A., R.Ph.
Full-time employees:10
City:Boca Raton
Address:777 Yamato Road
IPO:2016-10-11
CIK:0001604191

First Wave BioPharma, Inc., a clinical-stage biopharmaceutical company, engages in the research and development of targeted and non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its product candidates include niclosamide, an oral small molecule with anti-viral and anti-inflammatory properties; and the biologic adrulipase, a recombinant lipase enzyme designed to enable the digestion of fats and other nutrients. The company develops FW-COV, which is in Phase II clinical trials for the treatment of severe acute respiratory syndrome coronavirus 2 gastrointestinal infections; FW-UP, which is in Phase II clinical trials for the treatment ulcerative proctitis and ulcerative proctosigmoiditis; FW-ICI-AC for immune checkpoint inhibitor-associated colitis and diarrhea in advanced stage oncology patients; and FW-UC, which is in Phase Ib/IIa clinical trials for the treatment of ulcerative proctitis and ulcerative proctosigmoiditis. It also develops FW-CD, which has completed Phase I clinical trials for Crohn's disease; and adrulipase, an oral, non-systemic, and biologic capsule for the treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis and chronic pancreatitis. The company was formerly known as AzurRx BioPharma, Inc. and changed its name to First Wave BioPharma, Inc. in September 2021. First Wave BioPharma, Inc. was incorporated in 2014 and is headquartered in Boca Raton, Florida.

General Outlook

In simple terms, First Wave BioPharma, Inc. has 2.025 M shares that people are buying and selling right now.

Return on Investments

The company's asset efficiency, represented by a robust -2.297% return, is a testament to First Wave BioPharma, Inc.'s adeptness in optimizing resource deployment. First Wave BioPharma, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of -6.037%. Furthermore, the proficiency of First Wave BioPharma, Inc. in capital utilization is underscored by a remarkable -4.206% return on capital employed.

Stock Prices

First Wave BioPharma, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $4.58, while its low point bottomed out at $4.04. This variance in figures offers investors a lucid insight into the roller-coaster ride that is First Wave BioPharma, Inc.'s stock market.

Liquidity Ratios

Analyzing FWBI liquidity ratios reveals its financial health of the firm. The current ratio of 158.18% gauges short-term asset coverage for liabilities. The quick ratio (118.46%) assesses immediate liquidity, while the cash ratio (118.46%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio158.18%
Quick Ratio118.46%
Cash Ratio118.46%

Profitability Ratios

The effective tax rate stands at -0.13%, revealing its tax efficiency. The net income per EBT, 100.11%, and the EBT per EBIT, 100.15%, provide insights into its earnings hierarchy.

cards.indicatorcards.value
Effective Tax Rate-0.13%
Net Income per EBT100.11%
EBT per EBIT100.15%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 1.58, it details the span from stock purchase to revenue. The 1 days it takes to settle debts showcases its creditor relations.

cards.indicatorcards.value
Days of Sales Outstanding118
Days of Payables Outstanding2638
Payables Turnover0.14

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -7.93, and free cash flow per share, -8.25, depict cash generation on a per-share basis. The cash per share value, 2.38, showcases liquidity position. A payout ratio of -0.01 highlights the portion of earnings distributed as dividends.

cards.indicatorcards.value
Operating Cash Flow per Share-7.93
Free Cash Flow per Share-8.25
Cash per Share2.38
Payout Ratio-0.01
Free Cash Flow to Operating Cash Flow Ratio1.04
Cash Flow Coverage Ratio-14.97
Short Term Coverage Ratio-18.21
Capital Expenditure Coverage Ratio-24.76
Dividend Paid and Capex Coverage Ratio-21.07
Dividend Payout Ratio0.22

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 12.01%, highlights its total liabilities relative to assets. With a debt-equity ratio of 0.23, we discern the balance between debt and equity financing. The long-term debt to capitalization, 3.92%, and total debt to capitalization, 18.67%, ratios shed light on its capital structure. An interest coverage of -702.08 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio12.01%
Debt Equity Ratio0.23
Long Term Debt to Capitalization3.92%
Total Debt to Capitalization18.67%
Interest Coverage-702.08
Cash Flow to Debt Ratio-14.97
Company Equity Multiplier1.91

Per Share Data

Net income per share, -46.96, reflects the portion of profit attributed to each share. The book value per share, 10.71, represents the net asset value distributed per share, while the tangible book value per share, 5.70, excludes intangible assets.

cards.indicatorcards.value
Net Income Per Share-46.96
Book Value Per Share10.71
Tangible Book Value Per Share5.70
Shareholders Equity Per Share10.71
Interest Debt Per Share2.39
Capex Per Share-1.49

Growth Ratios

EBIT growth, -24.39%, and operating income growth, -24.39%, offer insights into operational profitability progression. The net income growth, 4.74%, showcases bottom-line expansion, and the EPS growth, 89.83%, measures the growth in earnings per share.

cards.indicatorcards.value
Gross Profit Growth72.44%
EBIT Growth-24.39%
Operating Income Growth-24.39%
Net Income Growth4.74%
EPS Growth89.83%
EPS Diluted Growth89.83%
Weighted Average Shares Growth836.57%
Weighted Average Shares Diluted Growth836.57%
Dividends per Share Growth-30.44%
Operating Cash Flow Growth44.60%
Free Cash Flow Growth42.37%
5-Year Operating CF Growth per Share97.51%
3-Year Operating CF Growth per Share99.78%
5-Year Net Income Growth per Share97.45%
3-Year Net Income Growth per Share99.92%
5-Year Shareholders Equity Growth per Share-98.24%
3-Year Shareholders Equity Growth per Share100.27%
3-Year Dividend per Share Growth per Share-99.99%
Receivables Growth-100.00%
Asset Growth26.54%
Book Value per Share Growth-85.97%
Debt Growth-6.43%
R&D Expense Growth628.13%
SGA Expenses Growth-10.67%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, -1,472,289.6, captures the company's total value, considering both debt and equity. Income quality, 0.78, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 24.47%, indicates the value of non-physical assets, and capex to operating cash flow, 4.04%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value-1,472,289.6
Income Quality0.78
Intangibles to Total Assets24.47%
Capex to Operating Cash Flow4.04%
Capex to Depreciation-1708.00%
Graham Number106.39
Return on Tangible Assets-303.81%
Graham Net Net1.28
Working Capital1,822,919
Tangible Asset Value1,918,747
Net Current Asset Value1,675,970
Average Receivables46,507
Average Payables637,158.5
Days Payables Outstanding6911
ROIC-344.59%
ROE-4.38%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, 1.48, and the price to book ratio, 1.48, reflect the market's valuation relative to the company's book value. Ratios like price to free cash flows, -0.54, and price to operating cash flows, -0.43, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio1.48
Price to Book Ratio1.48
Price Cash Flow Ratio-0.43
Enterprise Value Multiple-0.62
Price Fair Value1.48
Price to Operating Cash Flow Ratio-0.43
Price to Free Cash Flows Ratio-0.54
Price to Tangible Book Ratio0.39
Enterprise Value Over EBITDA0.09
EV to Operating Cash Flow0.12
Earnings Yield-1118.12%
Free Cash Flow Yield-911.62%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of First Wave BioPharma, Inc. (FWBI) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -0.338 in 2024.

What is the ticker symbol of First Wave BioPharma, Inc. stock?

The ticker symbol of First Wave BioPharma, Inc. stock is FWBI.

What is company IPO date?

IPO date of First Wave BioPharma, Inc. is 2016-10-11.

What is company current share price?

Current share price is 3.420 USD.

What is stock market cap today?

The market cap of stock today is 6925981.000.

What is PEG ratio in 2024?

The current 0.001 is 0.001 in 2024.

What is the number of employees in 2024?

In 2024 the company has 10.